Vevo Therapeutics is a biotechnology company based in San Francisco, focused on revolutionizing drug discovery using its proprietary Mosaic platform. The platform combines scalable in vivo data generation at single-cell precision with next-generation AI models. This approach allows Vevo to create a comprehensive atlas of how drugs interact with patient cells, capturing diverse responses and providing insights beyond traditional in vitro models.

The company was co-founded by Nima Alidoust, Hani Goodarzi, and Johnny Yu, leveraging technology licensed from UCSF. Vevo's methodology measures the effects of drugs on cells from hundreds of patients in a single experiment, producing extensive datasets on gene expression changes. The company aims to uncover novel drug targets and improve the success rate of treatments for diverse patient populations.